Combination of sunitinib and anti-CD40 monoclonal antibody treatment increases the expression of ICAM-1 and VCAM-1 on tumor endothelial cells, enhancing intratumoral infiltration of CD8+ cytotoxic T cells [52]. Here, VCAM1 is linked to neoplasm.